摘要
To investigate the clinicopathologic and molecular features of the T790M mutation and c-MET amplification in a cohort of Chinese non-small cell lung cancer (NSCLC) patients resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR TKI-resistant NSCLC patients (n = 29) and corresponding tumor specimens, and 53 samples of postoperative TKI-naive NSCLC patients were collected. EGFR exon 19, 20, and 21 mutations were analyzed. And c-MET gene copy number was determined. The EGFR T790M mutation in exon 20 was not detected in the population of 53 TKI-naive patients, but found in 48.3% (14/29) of the enrolled TKI-resistant patients. c-MET was amplified in 3.8% (2/53) of the TKI-naive NSCLC patients and highly amplified in 17.2% (5/29) of the cohort. Most of T790M mutations were frequently associated with non-smoker, adenocarcinoma and EGFR activating mutations. Three male patients with T790M mutation occurred with wild-type EGFR, and were resistant to the treatments following TKI resistance. Features of c-MET amplification in TKI-naive patients were indistinguishable from TKI-resistant patients. In the group of wild-type EGFR, patients with T790M mutation had median progression free survival (PFS) and overall survival (OS) as 9.6 months and 12.6 months, respectively; whereas the median PFS and OS of c-MET amplified patients was 4.1 months and 8.0 months, respectively. These results suggest that EGFR T790M mutation and c-MET amplification can occur in TKI-resistant NSCLC with wild-type EGFR, and these genetic defects might be related to different survival outcome. c-MET amplification in TKI-naive or -resistant patients might share similarities in clinicopathologic features.
学科与关键词
- Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancerPeng, Kai-Cheng; Su, Jun-Wei; Xie, Zhi; Wang, Han-Min; Fang, Mei-Mei; Li, Wen-Feng; Chen, Yu-Qing; Guan, Xu-Hui; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Tu, Hai-Yan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji*Thoracic Cancer, 2022, 13(11): 1619-1630.被引 5
- DYNAMIC, QUANTITATIVE, AND NON-INVASIVE ANALYSIS OFT790M MUTATION IN MATCHED PLASMA DNA FROM PRE-AND POST-EGFR-TKI TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCERChen Rui; Bai Hua; Wang Shuhang; Wang Yuyan; Duan Jianchun; Wang Jie; An Tongtong; Zhuo Minglei; Wu Meina
- Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapyLu, Yiyu; Li, Zhihua; Zhu, Huawei; Zhao, Juan; Xu, Mian; Gu, Weiguang*Annals of Palliative Medicine, 2021, 10(12): 12886-12893.被引 1
